Literature DB >> 25606821

Functional and Electrical Integration of Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Myocardial Infarction Rat Heart.

Takahiro Higuchi1, Shigeru Miyagawa, James T Pearson, Satsuki Fukushima, Atsuhiro Saito, Hirotsugu Tsuchimochi, Takashi Sonobe, Yutaka Fujii, Naoto Yagi, Alberto Astolfo, Mikiyasu Shirai, Yoshiki Sawa.   

Abstract

In vitro expanded beating cardiac myocytes derived from induced pluripotent stem cells (iPSC-CMs) are a promising source of therapy for cardiac regeneration. Meanwhile, the cell sheet method has been shown to potentially maximize survival, functionality, and integration of the transplanted cells into the heart. It is thus hypothesized that transplanted iPSC-CMs in a cell sheet manner may contribute to functional recovery via direct mechanical effects on the myocardial infarction (MI) heart. F344/NJcl-rnu/rnu rats were left coronary artery ligated (n = 30), followed by transplantation of Dsred-labeled iPSC-CM cell sheets of murine origin over the infarct heart surface. Effects of the treatment were assessed, including in vivo molecular/cellular evaluations using a synchrotron radiation scattering technique. Ejection fraction and activation recovery interval were significantly greater from day 3 onward after iPSC-CM transplantation compared to those after sham operation. A number of transplanted iPSC-CMs were present on the heart surface expressing cardiac myosin or connexin 43 over 2 weeks, assessed by immunoconfocal microscopy, while mitochondria in the transplanted iPSC-CMs gradually showed mature structure as assessed by electron microscopy. Of note, X-ray diffraction identified 1,0 and 1,1 equatorial reflections attributable to myosin and actin-myosin lattice planes typical of organized cardiac muscle fibers within the transplanted cell sheets at 4 weeks, suggesting cyclic systolic myosin mass transfer to actin filaments in the transplanted iPSC-CMs. Transplantation of iPSC-CM cell sheets into the heart yielded functional and electrical recovery with cyclic contraction of transplanted cells in the rat MI heart, indicating that this strategy may be a promising cardiac muscle replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25606821     DOI: 10.3727/096368914X685799

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  23 in total

1.  Three-Dimensional Adult Cardiac Extracellular Matrix Promotes Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Ashley H Fong; Mónica Romero-López; Christopher M Heylman; Mark Keating; David Tran; Agua Sobrino; Anh Q Tran; Hiep H Pham; Cristhian Fimbres; Paul D Gershon; Elliot L Botvinick; Steven C George; Christopher C W Hughes
Journal:  Tissue Eng Part A       Date:  2016-08       Impact factor: 3.845

Review 2.  Recent progress in induced pluripotent stem cell-derived 3D cultures for cardiac regeneration.

Authors:  Qi Xue; Kai-Li Wang; Xun-Hong Xu; Fang Hu; Hong Shao
Journal:  Cell Tissue Res       Date:  2021-02-05       Impact factor: 5.249

3.  N-cadherin overexpression enhances the reparative potency of human-induced pluripotent stem cell-derived cardiac myocytes in infarcted mouse hearts.

Authors:  Xi Lou; Meng Zhao; Chengming Fan; Vladimir G Fast; Mani T Valarmathi; Wuqiang Zhu; Jianyi Zhang
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

4.  Nano-imaging of the beating mouse heart in vivo: Importance of sarcomere dynamics, as opposed to sarcomere length per se, in the regulation of cardiac function.

Authors:  Fuyu Kobirumaki-Shimozawa; Kotaro Oyama; Togo Shimozawa; Akari Mizuno; Takashi Ohki; Takako Terui; Susumu Minamisawa; Shin'ichi Ishiwata; Norio Fukuda
Journal:  J Gen Physiol       Date:  2016-01       Impact factor: 4.086

Review 5.  Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart.

Authors:  Shigeru Miyagawa; Satsuki Fukushima; Yukiko Imanishi; Takuji Kawamura; Noriko Mochizuki-Oda; Shigeo Masuda; Yoshiki Sawa
Journal:  Curr Gene Ther       Date:  2016       Impact factor: 4.391

6.  Cardiomyocytes Derived from MHC-Homozygous Induced Pluripotent Stem Cells Exhibit Reduced Allogeneic Immunogenicity in MHC-Matched Non-human Primates.

Authors:  Takuji Kawamura; Shigeru Miyagawa; Satsuki Fukushima; Akira Maeda; Noriyuki Kashiyama; Ai Kawamura; Kenji Miki; Keisuke Okita; Yoshinori Yoshida; Takashi Shiina; Kazumasa Ogasawara; Shuji Miyagawa; Koichi Toda; Hiroomi Okuyama; Yoshiki Sawa
Journal:  Stem Cell Reports       Date:  2016-02-18       Impact factor: 7.765

7.  Dl-3-n-butylphthalide protects the heart against ischemic injury and H9c2 cardiomyoblasts against oxidative stress: involvement of mitochondrial function and biogenesis.

Authors:  Xiaochao Tian; Weiliang He; Rong Yang; Yingping Liu
Journal:  J Biomed Sci       Date:  2017-06-15       Impact factor: 8.410

8.  Enhanced Therapeutic Effects of Human iPS Cell Derived-Cardiomyocyte by Combined Cell-Sheets with Omental Flap Technique in Porcine Ischemic Cardiomyopathy Model.

Authors:  Masashi Kawamura; Shigeru Miyagawa; Satsuki Fukushima; Atsuhiro Saito; Kenji Miki; Shunsuke Funakoshi; Yoshinori Yoshida; Shinya Yamanaka; Tatsuya Shimizu; Teruo Okano; Takashi Daimon; Koichi Toda; Yoshiki Sawa
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

Review 9.  In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changin'.

Authors:  Isaac Perea-Gil; Cristina Prat-Vidal; Antoni Bayes-Genis
Journal:  Stem Cell Res Ther       Date:  2015-12-06       Impact factor: 6.832

10.  Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice.

Authors:  Ai Kawamura; Shigeru Miyagawa; Satsuki Fukushima; Takuji Kawamura; Noriyuki Kashiyama; Emiko Ito; Tadashi Watabe; Shigeo Masuda; Koichi Toda; Jun Hatazawa; Eiichi Morii; Yoshiki Sawa
Journal:  Sci Rep       Date:  2016-01-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.